https://feeds.newsfilecorp.com/company/12327 Latest news from Yellowbird Diagnostics, as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Wed, 15 Apr 2026 07:19:31 -0400 https://www.newsfilecorp.com/images/newswire/customer-logos/12327.jpg https://feeds.newsfilecorp.com/company/12327 https://www.newsfilecorp.com/release/292632/Yellowbird-Diagnostics-Announces-First-Patients-Dosed-in-Phase-1-Trial-of-NeuCavisTM Novel metabolic imaging agent identifies inflammation with high specificity First pipeline asset from Yellowbird's platform to enter clinical development Phase I trial evaluating NeuCaVis™ in healthy volunteers Phase I completion anticipated June 2026 Ottawa, Ontario--(Newsfile Corp. - April 15, 2026) - Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to...<img src="https://api.newsfilecorp.com/newsinfo/292632/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Wed, 15 Apr 2026 07:15:00 -0400 en https://www.newsfilecorp.com/release/292632 Novel metabolic imaging agent identifies inflammation with high specificity